PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Higher product revenue accompanied a quarterly net loss, while ST-920 added an upfront cost and potential regulatory milestone payments.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 revenue of $358 million and raised its full-year revenue outlook amid Sephience growth. Product revenue reached $275.9 million, versus $131.0 million a year earlier. Sephience generated $181.9 million, up 20% from the second quarter. Net loss was $51.7 million, compared with net income of $15.9 million a year earlier.
PTC now expects 2026 total revenue of $1.29–$1.32 billion and product revenue of $960–$990 million, previously $850–$950 million. It acquired Sangamo Therapeutics' ST-920 Fabry disease gene therapy for $111.0 million upfront, with up to $100.0 million in additional US approval milestones. PTC expects to complete its regulatory application in Q4 2026, with potential approval and launch in 2027. Cash and marketable securities totaled $2,127.9 million at September 30. The FDA meeting on votoplam is now scheduled for Q1 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3 total revenue rose to $357.807 million from $211.007 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.2026 revenue outlook raised to $1.29–$1.32 billion; product guidance increased to $960–$990 million from $850–$950 million.
- Moderate pointST-920 acquisition completed, adding Sangamo Therapeutics' Fabry disease gene therapy to PTC's pipeline.
- Moderate point. Forward-looking: it has not happened yet and may not happen.2026 cash flow breakeven remains on track, PTC said.
- Moderate pointQ3 operating income increased to $25.114 million from $3.016 million a year earlier.
14 minor points
- Minor pointQ3 product revenue increased over 100% year over year to $275.9 million from $131.0 million.
- Minor pointSephience Q3 revenue reached $181.9 million, up 20% from Q2 2026.
- Minor pointSephience active patients exceeded 2,000 worldwide as of September 30, 2026.
- Minor pointQ3 Evrysdi royalties increased to $81.7 million from $70.8 million a year earlier.
- Minor pointCash, equivalents and marketable securities increased to $2,127.9 million from $1,945.4 million at December 31, 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.ST-920 regulatory application completion expected in Q4 2026; potential FDA accelerated approval and launch in 2027.
- Minor pointQ3 selling, general and administrative expenses decreased to $80.1 million from $84.0 million a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Votoplam Phase 3 INVEST-HD is enrolling globally, targeting approximately 770 early symptomatic Huntington's disease patients.
- Minor pointVatiquinone PROVE-FA study began in Q3 2026 to support a Friedreich's ataxia application resubmission.
- Minor pointPTC844 Phase 2a study initiated; the PTC612 Phase 1 study remains ongoing.
- Minor point. Forward-looking: it has not happened yet and may not happen.PTC303, targeting MSH3, is expected to enter clinical testing in 2027.
- Minor pointNine-month research and development expenses decreased to $305.376 million from $322.121 million a year earlier.
- Minor pointNine-month selling, general and administrative expenses decreased to $246.894 million from $250.269 million a year earlier.
- Minor pointStockholders' deficit narrowed to $191.209 million from $205.313 million at December 31, 2025.
Negative
- Moderate pointQ3 net loss of $51.7 million replaced net income of $15.9 million a year earlier.
- Moderate pointST-920 upfront cost of $111.0 million was paid in cash and recorded as acquired research expense. 2.1% of market cap
- Moderate pointTotal debt increased to $536.268 million from $286.631 million at December 31, 2025.
- Moderate pointVotoplam FDA meeting is now scheduled for Q1 2027 due to FDA scheduling.
- Moderate pointQ3 Emflaza revenue declined to $25.1 million from $35.2 million a year earlier.
- Moderate pointNine-month total revenue decreased to $990.877 million from $1,565.978 million a year earlier.
- Moderate pointNine-month operating income decreased to $219.050 million from $938.284 million a year earlier.
- Moderate pointNine-month net income decreased to $28.994 million from $817.609 million a year earlier.
10 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.ST-920 contingent payments total up to an additional $100.0 million, based on US regulatory approvals.
- Minor pointQ3 Translarna revenue declined to $48.5 million from $50.7 million a year earlier.
- Minor pointQ3 research and development expenses increased to $105.4 million from $100.2 million a year earlier.
- Minor pointQ3 net interest expense increased to $45.866 million from $32.592 million a year earlier.
- Minor pointQ3 debt extinguishment loss was $19.263 million, versus none a year earlier.
- Minor pointQ3 sales costs excluding acquired-intangible amortization increased to $23.664 million from $15.781 million a year earlier.
- Minor pointQ3 acquired-intangible amortization increased to $12.595 million from $7.534 million a year earlier.
- Minor pointQ3 collaboration and license revenue declined to $0.229 million from $9.258 million a year earlier.
- Minor pointQ3 income tax expense of $10.605 million replaced a $38.970 million benefit a year earlier.
- Minor pointNine-month collaboration and license revenue decreased to $50.967 million from $998.430 million a year earlier.
News Explained
PTC Therapeutics reported 83,535,767 common shares outstanding on
Details
Market move: PTCT -3.80% vs previous close. 3Q26 earnings report
On Oct 29, the day this news came out, the latest delayed price for PTCT is 3.80% below the previous close. The latest delayed price is $62.01. Relative volume is above average at 1.6x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Total revenue
- $357.8 million
- Q3 2026
- Net product revenue
- $275.9 million
- Q3 2026; compared with $131.0 million in Q3 2025
- Sephience revenue
- $181.9 million
- Q3 2026; 20% growth versus Q2 2026
- Full-year total revenue guidance
- $1.29–$1.32 billion
- 2026 guidance, increased
- Full-year product revenue guidance
- $960–$990 million
- 2026 guidance, raised from $850–$950 million
- ST-920 acquisition consideration
- $111.0 million upfront; up to $100.0 million in contingent milestone payments
- Milestones based on US regulatory approvals
- Net loss
- $51.7 million
- Q3 2026, compared with net income of $15.9 million in Q3 2025
- ST-920 BLA submission
- Q4 2026
- Submission expected to be completed
Previous Earnings Reports
-
Sephience revenue reached $151.3 million and full-year product revenue guidance rose to $850–$950 million.
-
Product revenue was $226 million and full-year product revenue guidance rose to $750–$850 million.
-
Sephience launch generated $19.6 million in quarterly revenue, with 341 patients on commercial therapy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
aav medical
nda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Strong Q3 2026 performance with total revenue of
– Full-year 2026 expected total revenue increased to
– Sephience™ (sepiapterin) Q3 2026 revenue of
– Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 –
"We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year," said Matthew B. Klein, M.D., Chief Executive Officer. "Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally."
Key Corporate Updates
- Q3 2026 total revenue of
$358 million $276 million - Sephience launch momentum continues with steady growth in the US and ongoing global expansion
- Q3 2026 revenue of
$182 million $145 million $37 million 20% from Q2 2026 - Over 2,000 active patients worldwide as of September 30, 2026
- Q3 2026 revenue of
- ST-920 Fabry disease BLA submission expected to be completed in Q4 2026
- ST-920 is a one-time administered AAV gene therapy with the potential to reduce the burden associated with chronic enzyme replacement therapy
- Potential FDA accelerated approval and commercial launch in 2027
- Votoplam Huntington's disease program continues to advance
- Due to FDA scheduling, Type C meeting to discuss votoplam Phase 2 data and potential accelerated approval path now scheduled for Q1 2027
- Global Phase 3 INVEST-HD study actively enrolling at sites worldwide with target enrollment of approximately 770 early symptomatic patients
- Vatiquinone PROVE-FA study to support NDA resubmission for treatment of Friedreich's ataxia initiated in Q3 2026
- Global study will enroll approximately 120 patients ages 7 to 21
- Study includes open-label treatment arm with matched natural history control arm
- PTC pipeline advances across multiple programs
- Initiated Phase 2a study of PTC844, a next-generation DHODH inhibitor
- Ongoing Phase 1 study of PTC612, an oral NLRP3 inhibitor, continues to advance
- PTC303, a splicing development candidate targeting MSH3, expected to enter clinic in 2027
Third Quarter 2026 Financial Highlights
- Total net product revenue and royalty revenue was
$357.6 million $201.7 million - Total net product revenue across the commercial portfolio was
$275.9 million $131.0 million 100% increase. - Sephience net product revenues were
$181.9 million 20% growth compared to the second quarter of 2026. - Translarna™ (ataluren) net product revenues were
$48.5 million $50.7 million - Emflaza® (deflazacort) net product revenues were
$25.1 million $35.2 million - Roche reported Evrysdi® (risdiplam) year-to-date sales of approximately
CHF 1,470 million , resulting in royalty revenue of$81.7 million $70.8 million - Based on US GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were
$105.4 million $100.2 million - Non-GAAP R&D expenses were
$94.9 million $10.5 million $91.0 million $9.1 million - GAAP SG&A expenses were
$80.1 million $84.0 million - Non-GAAP SG&A expenses were
$66.7 million $13.3 million $73.8 million $10.3 million - Net loss was
$51.7 million $15.9 million - In Q3 2026, the Company acquired the ST-920 gene therapy for Fabry disease for
$111.0 million $100.0 million $111.0 million - Cash, cash equivalents, and marketable securities were
$2,127.9 million $1,945.4 - Shares issued and outstanding as of September 30, 2026, were 83,535,767.
PTC Updates Full-Year 2026 Financial Guidance
- Expected total revenue increased to
$1.29 $1.32 billion $960 $990 million $850 $950 million - GAAP R&D and SG&A expense guidance remains
$775 $815 million - Non-GAAP R&D and SG&A expense guidance remains
$680 $720 million $95 million
Non-GAAP Financial Measures
In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.
|
PTC Therapeutics, Inc. |
|||||||||||
|
Consolidated Statements of Operations |
|||||||||||
|
(in thousands, except share and per share data) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September |
|
Nine Months Ended September |
||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
|
Revenues: |
|
|
|
|
|
|
|
||||
|
Net product revenue |
$ |
275,894 |
|
$ |
130,956 |
|
$ |
740,286 |
|
$ |
402,711 |
|
Collaboration and license revenue |
|
229 |
|
9,258 |
|
50,967 |
|
998,430 |
|||
|
Royalty revenue |
|
81,684 |
|
70,793 |
|
199,624 |
|
164,837 |
|||
|
Total revenues |
357,807 |
|
211,007 |
|
990,877 |
|
1,565,978 |
||||
|
Operating expenses: |
|
|
|
|
|
|
|
||||
|
Cost of product, collaboration and license sales, excluding |
23,664 |
|
15,781 |
|
71,613 |
|
40,063 |
||||
|
Amortization of acquired intangible assets |
12,595 |
|
7,534 |
|
36,017 |
|
15,393 |
||||
|
Research and development (1) |
105,353 |
|
100,158 |
|
305,376 |
|
322,121 |
||||
|
Selling, general and administrative (2) |
80,081 |
|
84,046 |
|
246,894 |
|
250,269 |
||||
|
Change in the fair value of contingent consideration |
- |
|
- |
|
- |
|
(800) |
||||
|
Tangible asset impairment and losses on transactions, net |
|
- |
|
|
472 |
|
|
927 |
|
|
648 |
|
Acquired in-process research and development * |
|
111,000 |
|
|
- |
|
|
111,000 |
|
|
- |
|
Total operating expenses |
332,693 |
|
207,991 |
|
771,827 |
|
627,694 |
||||
|
Income from operations |
25,114 |
|
3,016 |
|
219,050 |
|
938,284 |
||||
|
Interest expense, net |
(45,866) |
|
(32,592) |
|
(143,377) |
|
(97,042) |
||||
|
Other (expense) income, net |
(1,073) |
|
6,502 |
|
(2,415) |
|
(5,540) |
||||
|
Loss on extinguishment of debt |
|
(19,263) |
|
|
- |
|
(19,263) |
|
|
- |
|
|
(Loss) income before income tax (expense) benefit |
(41,088) |
|
(23,074) |
|
53,995 |
|
835,702 |
||||
|
Income tax (expense) benefit |
(10,605) |
|
38,970 |
|
(25,001) |
|
(18,093) |
||||
|
Net (loss) income attributable to common stockholders |
$ |
(51,693) |
|
$ |
15,896 |
|
$ |
28,994 |
|
$ |
817,609 |
|
|
|
|
|
|
|
|
|
||||
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
||||
|
Basic (in shares) |
83,476,100 |
|
78,471,119 |
|
83,004,625 |
|
78,642,478 |
||||
|
Diluted (in shares) |
83,476,100 |
|
|
87,115,369 |
|
92,253,675 |
|
|
86,899,727 |
||
|
Net (loss) income per share—basic (in dollars per share) |
$ |
(0.62) |
|
$ |
0.20 |
|
$ |
0.35 |
|
$ |
10.40 |
|
Net (loss) income per share—diluted (in dollars per share) |
$ |
(0.62) |
|
$ |
0.20 |
|
$ |
0.34 |
|
$ |
9.45 |
|
|
|
|
|
|
|
|
|
||||
|
(1) Research and development reconciliation |
|
|
|
|
|
|
|
||||
|
GAAP research and development |
$ |
105,353 |
|
$ |
100,158 |
|
$ |
305,376 |
|
$ |
322,121 |
|
Less: share-based compensation expense |
10,479 |
|
9,133 |
|
32,155 |
|
26,827 |
||||
|
Non-GAAP research and development |
$ |
94,874 |
|
$ |
91,025 |
|
$ |
273,221 |
|
$ |
295,294 |
|
|
|
|
|
|
|
|
|
||||
|
(2) Selling, general and administrative reconciliation |
|
|
|
|
|
|
|
||||
|
GAAP selling, general and administrative |
$ |
80,081 |
|
$ |
84,046 |
|
$ |
246,894 |
|
$ |
250,269 |
|
Less: share-based compensation expense |
13,348 |
|
10,293 |
|
38,384 |
|
29,202 |
||||
|
Non-GAAP selling, general and administrative |
$ |
66,733 |
|
$ |
73,753 |
|
$ |
208,510 |
|
$ |
221,067 |
|
|
|
* In Q3 2026, the Company purchased the ST-920 asset from Sangamo Therapeutics, Inc. and paid an upfront cash consideration of |
|
PTC Therapeutics, Inc. |
||||||
|
Summary Consolidated Balance Sheets |
||||||
|
(in thousands, except share data) |
||||||
|
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
||
|
Cash, cash equivalents and marketable securities |
$ |
2,127,918 |
|
$ |
1,945,371 |
|
|
Total Assets |
$ |
3,207,715 |
|
$ |
2,898,767 |
|
|
|
|
|
|
|
|
|
|
Total debt |
$ |
536,268 |
|
$ |
286,631 |
|
|
Total deferred revenue |
|
1,975 |
|
|
2,040 |
|
|
Total liability for sale of future royalties |
|
2,305,603 |
|
|
2,308,366 |
|
|
Total liabilities |
$ |
3,398,924 |
|
$ |
3,104,080 |
|
|
|
|
|
|
|
|
|
|
Total stockholders' deficit (83,535,767 and 81,474,366 common shares |
$ |
(191,209) |
|
$ |
(205,313) |
|
|
Total liabilities and stockholders' deficit |
$ |
3,207,715 |
|
$ |
2,898,767 |
|
|
PTC Therapeutics, Inc. |
|||||
|
Reconciliation of GAAP to Non-GAAP Projected Full Year 2026 R&D and SG&A Expense |
|||||
|
(in millions) |
|||||
|
|
|||||
|
|
|
|
|
|
|
|
|
Low End of Range |
|
High End of Range |
||
|
Projected GAAP R&D and SG&A Expense |
$ |
775 |
|
$ |
815 |
|
Less: projected non-cash, stock-based compensation expense |
95 |
|
95 |
||
|
Projected non-GAAP R&D and SG&A expense |
$ |
680 |
|
$ |
720 |
Acronyms
AAV: adeno-associated virus
BLA: Biologics License Application
CHF: Confoederatio Helvetica Francs (Swiss francs)
DHODH: dihydroorotate dehydrogenase
FA: Friedreich's ataxia
FDA: US Food and Drug Administration
GAAP: Generally Accepted Accounting Principles
HD: Huntington's disease
MSH3: MutS Homolog 3 (human gene)
NDA: New Drug Application
NLRP3: NOD-, LRR- and pyrin domain-containing 3 (multi-protein complex)
R&D: Research and Development
SG&A: Selling, General, and Administrative
Today's Conference Call and Webcast Reminder
To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on LinkedIn, X, Facebook and Instagram.
For more information please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "PTC Updates Full-Year 2026 Financial Guidance", including with respect to (i) 2026 total product revenue guidance and total revenue guidance and (ii) 2026 GAAP and non-GAAP R&D and SG&A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, meetings with regulatory agencies, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance," "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," "aim," and similar expressions.
PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including commercialization and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in geographies in which it has been approved and the effect of the European Commission's adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna and the withdrawal of the Translarna NDA in the US on other regulatory bodies; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; expectations with respect to ST-920, including the expected timing of regulatory submissions and potential approvals, and the potential achievement of regulatory milestones and contingent payments PTC may be obligated to make; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including with respect to the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses and potential approvals and other matters; expectations with respect to the commercialization of Evrysdi under PTC's SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; expectations regarding PTC's product candidates, including the timing of clinical trials and studies; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.
As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience, Translarna, Emflaza, Upstaza, Kebilidi, Evrysdi, Tegsedi or Waylivra.
The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.
View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html
SOURCE PTC Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is PTC Therapeutics' updated 2026 revenue guidance?
PTC expects $1.29–$1.32 billion in total revenue and $960–$990 million in product revenue for 2026. The product revenue range increased from $850–$950 million. Full-year research and development plus selling, general and administrative expense guidance remains $775–$815 million under generally accepted accounting principles.
How much did PTC Therapeutics pay for ST-920, and when could it launch?
PTC paid $111.0 million upfront for ST-920, with up to an additional $100.0 million in contingent payments based on US regulatory approvals. PTC expects to complete the biologics license application in Q4 2026, with potential FDA accelerated approval and commercial launch in 2027.
How is PTC Therapeutics' vatiquinone PROVE-FA study designed?
The PROVE-FA study will enroll approximately 120 patients ages 7 to 21 and includes an open-label treatment arm with a matched natural history control arm. It began in Q3 2026 to support resubmission of the new drug application for Friedreich's ataxia.
What will PTC Therapeutics discuss at the votoplam FDA meeting?
The Type C meeting will discuss votoplam Phase 2 data and a potential accelerated approval path for Huntington's disease. The meeting is now scheduled for Q1 2027 due to FDA scheduling.
Did PTC Therapeutics' third-quarter Translarna revenue include a government order?
Translarna's third-quarter 2026 revenue included a government purchase order from Russia. Total Translarna revenue for the quarter was $48.5 million, compared with $50.7 million a year earlier.